|Bid||3.9600 x 800|
|Ask||7.9500 x 800|
|Day's Range||4.0600 - 4.3300|
|52 Week Range||4.0400 - 9.7500|
|Beta (3Y Monthly)||2.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.14|
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -27.91% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 59 cents. Losses, adjusted for restructuring costs, came to 55 cents per share. The results did not meet Wall Street ...
- Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs –
NEW YORK, NY / ACCESSWIRE / May 2, 2019 / Seres Therapeutics, Inc. (NASDAQ: MCRB ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 2, 2019 at 8:30 AM Eastern ...
To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 3368968. Seres Therapeutics, Inc. (MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ SER-287 program has obtained Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis.
Big Pharma is rapidly increasing its investments into biotech companies aiming to treat disease by targeting the microbiome. Some are also working on using bacterial strains as drugs.
“The novel data presented at AACR provide mechanistic insights into the biological activity of our microbiome therapeutic candidates to augment immune checkpoint inhibitors,” said Matthew Henn, Ph.D., Chief Scientific Officer and Executive Vice President at Seres. Seres presented preclinical results evaluating the impact of various consortia of bacterial species on the anti-tumor immune response in murine models following treatment with an anti-PD-1 checkpoint inhibitor.
Microbiome-focused biotech Seres Therapeutics is teaming up with drug giant AstraZeneca to explore how the trillions of bacteria in a person’s gut could help fight cancer.
- Collaboration focused on further elucidating the potential of microbiome therapeutics to augment immuno-oncology treatment for cancer –
- Initiated SER-287 Phase 2b study in mild-to-moderate ulcerative colitis -
Seres Therapeutics, Inc. today announced that it will present at each of the following upcoming healthcare conferences:
Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on March 6, 2019 at 8:30 a.m. ET to discuss fourth quarter and full year 2018 results and provide a general business update.
“We believe that microbiome therapeutics have an important role in the future of medicine for a range of serious diseases and that Seres is well positioned to drive progress in the field with our late-stage clinical-stage programs, differentiated drug discovery and state-of-the-art manufacturing capabilities. Following a comprehensive review of our pipeline, we are concentrating our resources on obtaining clinical results from our highest-priority, late-stage clinical programs in ulcerative colitis and C. difficile infection as well as our soon-to-be initiated Phase 1b study in patients with metastatic melanoma,” said Eric Shaff, President and Chief Executive Officer of Seres Therapeutics.
Mr. Shaff, who is currently Chief Operating and Financial Officer, succeeds Roger J. Pomerantz, M.D. Mr. Shaff has also joined Seres’ Board of Directors and will continue to serve as Seres’ principal financial officer on an interim basis. Dr. Pomerantz will continue as Chairman of Seres’ Board of Directors.
Roger Pomerantz has been the CEO of Seres Therapeutics, Inc. (NASDAQ:MCRB) since 2014. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
“Advancing SER-287 into a late stage Phase 2B trial is a significant achievement,” said Kevin Horgan, M.D., Executive Vice President and Chief Medical Officer. “We are hopeful that SER-287 may provide individuals with ulcerative colitis with a novel microbiome-based, non-immunosuppressive therapy that addresses the underlying pathology of this serious disease. The SER-287 Phase 2B ECO-RESET study has been designed as a pivotal trial.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Seres Therapeutics, Inc. today announced that it will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13th at 9:30 a.m. ET.